Julia White

Eli Lilly (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

52h-index12.8kcitations349works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(236), Advanced Radiotherapy Techniques(86), Breast Lesions and Carcinomas(74), Breast Implant and Reconstruction(38), Cancer Treatment and Pharmacology(34)

Publications345 total

Use of Magnetic Resonance Imaging to Guide Preoperative Accelerated Partial Breast Irradiation in the Prone Position and Treatment Response in Clinical Stage 1 Hormone Sensitive Breast Cancer: A Phase 1/2 Study
International Journal of Radiation Oncology*Biology*Physics·2025Open Access
Methodological and reporting rigor in noninferiority and equivalence trials for multimodality cancer treatment: lessons from breast cancer radiotherapy
Journal of Clinical Epidemiology·2025
Benchmarking the Current Landscape: Insights From an Association of American Cancer Institutes Survey on Academic Cancer Service Lines
JCO Oncology Practice·2025Open Access
Analysis of the Radiosensitivity Index in Paired Preneoadjuvant and Postneoadjuvant Therapy Triple-Negative Breast Cancer
International Journal of Radiation Oncology*Biology*Physics·2025· 1 citedOpen Access
Acute Toxicity in SWOG 1706, a Randomized Trial Comparing Radiotherapy for Inflammatory Breast Cancer with and without Concurrent Olaparib
International Journal of Radiation Oncology*Biology*Physics·2025
Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer
JAMA Oncology·2025· 1 citedOpen Access
Erratum: De Novo Oligometastatic Breast Cancer
Journal of Clinical Oncology·2025
NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer
Future Oncology·2025· 2 cited
Abstract P3-12-20: NRG-BR009: A phase III trial evaluating addition of adjuvant chemotherapy to Ovarian Function Suppression + Endocrine Therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and Oncotype Recurrence Score (RS) ≤25 (OFSET)
Clinical Cancer Research·2025· 1 cited
Abstract P5-09-09: Prospective Evaluation of Shoulder Morbidity in Patients with Lymph Node-Positive Breast Cancer Receiving Regional Nodal Irradiation
Clinical Cancer Research·2025
Abstract RF1-01: Effect of a weight loss intervention (WLI) on metabolic and inflammatory biomarkers in women with obesity and breast cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial (Alliance)
Clinical Cancer Research·2025
Abstract P2-01-21: Baseline circulating tumor cells (CTCs) predict for progression-free survival (PFS) after ablation on NRG-BR002, a randomized phase II/III study of ablation vs. standard systemic therapy care (SOC) for oligometastatic breast cancer (OMBC)
Clinical Cancer Research·2025· 2 cited
Abstract P3-12-19: NRG-BR008: A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO)
Clinical Cancer Research·2025
Abstract P3-06-15: Trajectories of Daily Step Counts in Breast Cancer Survivors in the Breast Cancer Weight Loss (BWEL) Trial
Clinical Cancer Research·2025
Abstract P2-12-25: A phase III trial evaluating De-escalation of Breast Radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer: NRG-BR007
Clinical Cancer Research·2025
Analytical Comparison of Commonly Used Laboratory-Developed Tests for the Assessment of Ki-67 in Breast Carcinoma With a Food and Drug Administration–Approved Benchmark
Modern Pathology·2025Open Access
Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy
New England Journal of Medicine·2025· 45 citedOpen Access
NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer.
Journal of Clinical Oncology·2025
Intervention adherence, engagement and tool utilization in the breast cancer weight loss (BWEL) trial by race and ethnicity (Alliance A011401).
Journal of Clinical Oncology·2025
Association of lifestyle factors and pathological characteristics in patients with early breast cancer and overweight/obesity: Results from the Breast Cancer Weight Loss (BWEL) trial.
Journal of Clinical Oncology·2025
page 1 of 18Next →

Frequent Co-authors

Frank A. Vicini(19), Douglas W. Arthur(15), Kathryn Winter(12), Rachel Rabinovitch(10), Beryl McCormick(10), Bruce G. Haffty(8), Benjamin D. Smith(7), Robert R. Kuske(7), Jennifer Moughan(7), Lori J. Pierce(6), Thomas B. Julian(6), X. Allen Li(6), Timothy J. Whelan(5), J. Frank Wilson(5), Thomas A. Buchholz(4), Dorin Todor(4), Jay R. Harris(4), Hania Al‐Hallaq(4), Steven J. Chmura(4), Soonmyung Paik(4)